Paragon 28 Intrinsic Value – Paragon 28 Set to Report Third Quarter Financial Results on November 7, 2023
October 21, 2023
🌥️Trending News
Paragon 28 ($NYSE:FNA) is set to report their third quarter financial results on November 7, 2023. This announcement comes at an exciting time for investors, as the company has seen significant growth in recent years. Paragon 28 is a leading provider of innovative healthcare solutions in the United States and abroad. Their products and services are designed to provide cost-effective and efficient healthcare solutions to the world’s most pressing needs. They have a well-established network of strategic partners, enabling them to reach patients and provide comprehensive care across the United States and around the world. Their comprehensive portfolio of products and services provide unique value for customers while optimizing operational efficiencies for healthcare organizations.
They offer innovative products such as their patented telehealth platform, cloud-based enterprise data systems, and integrated patient management systems. With a broad range of technology, they are able to provide customers with tailored solutions that help them navigate the ever-changing healthcare landscape. With a clear vision and commitment to innovation, they are well-positioned to continue their growth trajectory in the healthcare sector. Investors should be watching closely for the release of these financial results to gain insight into the future of the company and its prospects for future success.
Stock Price
In anticipation of the announcement, the company’s stock opened at $9.3 and closed at $8.9, representing a 6.2% drop from its last closing price of $9.5. This decrease in PARAGON 28‘s stock price indicates that investors are expecting to see a decline in the company’s financial performance. It is yet to be seen whether the financial report will live up to these expectations, but investors will be eagerly awaiting the outcome when it is released later this week. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Paragon 28. More…
| Total Revenues | Net Income | Net Margin |
| 200.56 | -68.44 | -26.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Paragon 28. More…
| Operations | Investing | Financing |
| -58.74 | -27.98 | 70.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Paragon 28. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 300.84 | 101.8 | 2.41 |
Key Ratios Snapshot
Some of the financial key ratios for Paragon 28 are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.5% | – | -31.9% |
| FCF Margin | ROE | ROA |
| -43.7% | -19.8% | -13.3% |
Analysis – Paragon 28 Intrinsic Value
At GoodWhale, we conducted an analysis on PARAGON 28‘s wellbeing and are pleased to present our findings. Our proprietary Valuation Line calculated the fair value of PARAGON 28 shares to be around $18.9. However, the stock is currently being traded at $8.9, resulting in an undervaluation of 52.9%. We believe this presents an attractive investment opportunity and would recommend investors take advantage of this situation. More…
Peers
The company was founded in 2013 and is headquartered in San Diego, California. Paragon 28‘s competitors include Avra Medical Robotics Inc, Armm Inc, Implanet SA.
– Avra Medical Robotics Inc ($OTCPK:AVMR)
Avra Medical Robotics Inc is a medical technology company that focuses on the development and commercialization of robot-assisted surgery systems. The company’s products are designed to improve the safety and efficiency of surgical procedures. Avra Medical Robotics Inc has a market cap of 317.5k as of 2022, a Return on Equity of 231.87%. The company’s products are used in a variety of surgical procedures, including orthopedic, urological, and gynecological procedures.
– Armm Inc ($OTCPK:ARMM)
Implanet SA is a French company that designs, manufactures, and markets medical devices for orthopedic surgery. The company was founded in 2001 and has a market capitalization of 5.51 million as of 2022. The company’s return on equity is -114.56%.
The company’s products are used in the treatment of conditions such as osteoarthritis, degenerative disc disease, and scoliosis. The company’s products are sold in over 50 countries worldwide.
Summary
Investing in Paragon 28 can be a lucrative opportunity for investors, as the company is set to report its third quarter financial results on November 7, 2023. Analysts are expecting to see an increase in revenue and profits from the previous quarter.
In addition, potential investors should research the company’s management team, products, services, and industry to determine whether it is a good fit for their investing goals. On the day that the results were announced, Paragon 28’s stock price moved slightly down, likely due to increased market volatility and uncertainty. Nonetheless, investing in this company could be a wise move for those looking for long-term growth potential. Investors should use fundamental and technical analysis to decide if Paragon 28 is a good choice for them.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
